Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
Hinge Bio, a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined […]
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer […]
Asieris Appoints Dr. Linda Wu as Chief Development Officer
Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more